Garda Capital Partners’s AbbVie ABBV Stock Holding History

Garda Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,027	Closed	-$489K	–	348
2022 Q4	$489K	Buy	+3,027	New	+$464K	0.03%	348

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Garda Capital Partners's ABBV Position: Q1 2023 in Review

Garda Capital Partners sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 3,027 shares — an estimated $489K sold.

Garda Capital Partners first reported a position in ABBV in Q4 2022 and held it in 1 quarter. The position peaked at $489K in Q4 2022. 3,139 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Garda Capital Partners reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
Garda Capital Partners sold 3,027 AbbVie shares in Q1 2023, an estimated $489K.
Garda Capital Partners first reported a position in AbbVie in Q4 2022 and held it in 1 quarter.
Garda Capital Partners's AbbVie position peaked at $489K in Q4 2022.
3,139 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Garda Capital Partners's 13F filing for Q1 2023, filed 10 May 2023.